SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from TANDEM DIABETES CARE INC (TNDM) (CIK 0001438133) (TNDM) — Feb 8, 2018

TANDEM DIABETES CARE INC (TNDM) (CIK 0001438133)
Date: Feb. 8, 2018 · CIK: 0001438133 · Accession: 0001193125-18-035364

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-222553

Date
February 7, 2018
Author
/s/ David B. Berger
Form
CORRESP
Company
TANDEM DIABETES CARE INC (TNDM) (CIK 0001438133)

Letter

Tandem Diabetes Care, Inc.

11075 Roselle Street

San Diego, CA 92121

February 7, 2018

SUBMITTED VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E. Washington, D.C. 20549

Attention: Tom Jones

Re: Tandem Diabetes Care, Inc.

Registration Statement on Form S-1 (File No. 333-222553)

Acceleration Request

Requested Date:

February 8, 2018

Requested Time:

4:00 P.M., Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statements on Form S-1 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, unless you are notified by telephone or in writing to the contrary by the Company prior to such “Requested Date” and “Requested Time.” In the event you are so notified, you will be contacted either by Ryan C. Wilkins, an attorney with the Company’s outside legal counsel, Stradling Yocca Carlson & Rauth, P.C., or by myself.

Should the Commission have questions regarding any of the foregoing, please do not hesitate to contact Mr. Wilkins, via telephone at (949) 725-4115 or via email at rwilkins@sycr.com, or in his absence, please contact me via telephone at (858) 255-6380 or via email at dberger@tandemdiabetes.com.

We respectfully request that you contact Mr. Wilkins via telephone as soon as the Registration Statement has been declared effective.

Sincerely,
TANDEM DIABETES CARE, INC.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 Tandem Diabetes Care, Inc.

11075 Roselle Street

 San
Diego, CA 92121

 February 7, 2018

SUBMITTED VIA EDGAR

 Securities and Exchange Commission

 Division of Corporation Finance

 100 F Street, N.E.
Washington, D.C. 20549

 Attention: Tom Jones

Re:
Tandem Diabetes Care, Inc.

 Registration Statement on Form S-1 (File
No. 333-222553)

 Acceleration Request

Requested Date:

February 8, 2018

Requested Time:

4:00 P.M., Eastern Time

 Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Tandem Diabetes Care, Inc., a Delaware corporation (the
“Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statements on Form S-1 effective at the
“Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, unless you are notified by telephone or in writing to the contrary by the Company prior to such “Requested Date” and
“Requested Time.” In the event you are so notified, you will be contacted either by Ryan C. Wilkins, an attorney with the Company’s outside legal counsel, Stradling Yocca Carlson & Rauth, P.C., or by myself.

Should the Commission have questions regarding any of the foregoing, please do not hesitate to contact Mr. Wilkins, via telephone at
(949) 725-4115 or via email at rwilkins@sycr.com, or in his absence, please contact me via telephone at (858) 255-6380 or via email at dberger@tandemdiabetes.com.

 We respectfully request that you contact Mr. Wilkins via telephone as soon as the
Registration Statement has been declared effective.

Sincerely,

TANDEM DIABETES CARE, INC.

/s/ David B. Berger

David B. Berger

General Counsel

 cc:

Tandem Diabetes Care, Inc.

Kim D. Blickenstaff, Chief Executive Officer

Leigh Voseller, Chief Financial Officer

Clifford Chance US LLP

Per B. Chilstrom, Esq.

Stradling Yocca Carlson & Rauth, P.C.

Bruce Feuchter, Esq.

 Ryan C.
Wilkins, Esq.